Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines.

Geeleher P, Cox NJ, Huang RS.

Genome Biol. 2014 Mar 3;15(3):R47. doi: 10.1186/gb-2014-15-3-r47.

PMID:
24580837
[PubMed - in process]
Free PMC Article
2.

pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels.

Geeleher P, Cox N, Huang RS.

PLoS One. 2014 Sep 17;9(9):e107468. doi: 10.1371/journal.pone.0107468. eCollection 2014.

PMID:
25229481
[PubMed - in process]
Free Article
3.

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity.

Hsu YC, Chen HY, Yuan S, Yu SL, Lin CH, Wu G, Yang PC, Li KC.

BMC Med. 2013 Apr 16;11:106. doi: 10.1186/1741-7015-11-106.

PMID:
23590835
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.

Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg JP, Bertucci F, Gonçalves A.

Breast Cancer Res Treat. 2012 Apr;132(3):1035-47. doi: 10.1007/s10549-011-1687-8. Epub 2011 Jul 27. Erratum in: Breast Cancer Res Treat. 2012 Jul;134(1):449-51.

PMID:
21792624
[PubMed - indexed for MEDLINE]
5.

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2007 Dec;8(12):1071-8. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.

PMID:
18024211
[PubMed - indexed for MEDLINE]
6.

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.

Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP.

BMC Genomics. 2006 Nov 10;7:289.

PMID:
17096850
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.

Knudsen S, Jensen T, Hansen A, Mazin W, Lindemann J, Kuter I, Laing N, Anderson E.

PLoS One. 2014 Feb 5;9(2):e87415. doi: 10.1371/journal.pone.0087415. eCollection 2014.

PMID:
24505287
[PubMed - in process]
Free PMC Article
8.

A pharmacogenomic method for individualized prediction of drug sensitivity.

Cohen AL, Soldi R, Zhang H, Gustafson AM, Wilcox R, Welm BE, Chang JT, Johnson E, Spira A, Jeffrey SS, Bild AH.

Mol Syst Biol. 2011 Jul 19;7:513. doi: 10.1038/msb.2011.47.

PMID:
21772261
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.

Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L.

Breast Cancer Res Treat. 2010 Jun;121(2):301-9. doi: 10.1007/s10549-009-0445-7. Epub 2009 Jul 15.

PMID:
19603265
[PubMed - indexed for MEDLINE]
10.

Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer.

Lee SC, Xu X, Chng WJ, Watson M, Lim YW, Wong CI, Iau P, Sukri N, Lim SE, Yap HL, Buhari SA, Tan P, Guo J, Chuah B, McLeod HL, Goh BC.

Pharmacogenet Genomics. 2009 Nov;19(11):833-42. doi: 10.1097/FPC.0b013e328330a39f.

PMID:
19809382
[PubMed - indexed for MEDLINE]
11.

Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

Györffy B, Serra V, Jürchott K, Abdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R.

Oncogene. 2005 Nov 17;24(51):7542-51.

PMID:
16044152
[PubMed - indexed for MEDLINE]
12.

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, Dougherty B, Ducreux M, Soria JC, Friend S, Derry J, Laurent-Puig P.

Clin Cancer Res. 2014 Jan 1;20(1):265-72. doi: 10.1158/1078-0432.CCR-13-1943. Epub 2013 Oct 29.

PMID:
24170544
[PubMed - indexed for MEDLINE]
13.

Predicting in vitro drug sensitivity using Random Forests.

Riddick G, Song H, Ahn S, Walling J, Borges-Rivera D, Zhang W, Fine HA.

Bioinformatics. 2011 Jan 15;27(2):220-4. doi: 10.1093/bioinformatics/btq628. Epub 2010 Dec 5.

PMID:
21134890
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Improving the prediction of chemotherapeutic sensitivity of tumors in breast cancer via optimizing the selection of candidate genes.

Jiang L, Huang L, Kuang Q, Zhang J, Li M, Wen Z, He L.

Comput Biol Chem. 2014 Apr;49:71-8. doi: 10.1016/j.compbiolchem.2013.12.002. Epub 2014 Jan 1.

PMID:
24440656
[PubMed - in process]
15.

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.

Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A.

PLoS One. 2008 Apr 2;3(4):e1908. doi: 10.1371/journal.pone.0001908. Retraction in: PLoS One. 2011;6(9). doi: 10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4.

PMID:
18382681
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical data.

Smit EF, de Vries EG, Timmer-Bosscha H, de Leij LF, Oosterhuis JW, Scheper RJ, Weening JJ, Postmus PE, Mulder NH.

Int J Cancer. 1992 Apr 22;51(1):72-8.

PMID:
1314232
[PubMed - indexed for MEDLINE]
17.

Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.

Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH.

Am J Respir Crit Care Med. 2010 Jan 15;181(2):181-8. doi: 10.1164/rccm.200812-1807OC. Epub 2009 Oct 15.

PMID:
19833826
[PubMed - indexed for MEDLINE]
18.

Automated brain tumor biopsy prediction using single-labeling cDNA microarrays-based gene expression profiling.

Castells X, García-Gómez JM, Navarro A, Acebes JJ, Godino O, Boluda S, Barceló A, Robles M, Ariño J, Arús C.

Diagn Mol Pathol. 2009 Dec;18(4):206-18. doi: 10.1097/PDM.0b013e31818f071b.

PMID:
19861896
[PubMed - indexed for MEDLINE]
19.

Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.

Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, Elmore SW, Kroeger PE, Tse C, Rosenberg SH, Anderson MG.

Mol Cancer Ther. 2010 Mar;9(3):545-57. doi: 10.1158/1535-7163.MCT-09-0651. Epub 2010 Feb 23.

PMID:
20179162
[PubMed - indexed for MEDLINE]
Free Article
20.

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr.

Mol Cancer Res. 2006 Aug;4(8):521-8.

PMID:
16877703
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk